Sign in to fuzzto save your conversations, follow your research and come back anytime.
Novartis
SectorHealthcare
In the news
Novartis-Abogen Sign $7.8B Deal for mRNA Autoimmune Therapies
Stock Performance Drivers: Demergers, IPOs, and Sectoral Shifts
Novartis India zooms 51% in 3 days after ₹1,250 crore Pfizer acquisition
Novartis India secures retina portfolio rights, targets acquisitions
Novartis Drug Trial Failures Hit Stock Hard Amid Market Volatility
ChrysCapital completes ₹1,446 crore acquisition of Novartis India
Novartis launches India's first radioligand therapy for prostate cancer
Novartis exits Indian arm for ₹1,446cr to ChrysCapital-led group
Novartis India shares surge 17% as ChrysCapital consortium completes buyout
Company insights, generated from the most recent coverage.
Novartis India acquired Minipress XL trademarks and IP from Pfizer for ₹1,250 Cr, gaining a growing hypertension/BPH franchise (₹228 Cr revenue, 6.3% CAGR) while competitor Pfizer India exits the brand.
Minimal crude oil sensitivity due to low dependence on crude-derived inputs; fortress balance sheet with 5.13 current ratio and 0.01 debt-to-equity provides financial flexibility during volatility.
Acquired Minipress and Minipres trademarks from Pfizer for ₹1,250 crore to strengthen cardiovascular and urology portfolio.